Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.

Inclusion Criteria: * Adult patients with no upper age limit, * Scheduled cardiac surgery with cardiopulmonary bypass, * Patients with preoperative thrombocytopenia strictly \<150,000/mm3 * Surgery performed with a blood recovery system using centrifugation (Cell Saver type) or equivalent, * Feasibility of a first injection (Romiplostim or Placebo) between D-14 and D-10 before surgery, * Surgery requiring the administration of antiplatelet and/or anticoagulant therapy for a minimum of 1 month postoperatively. Exclusion Criteria: * Inability to administer the first injection of Romiplostim or Placebo within 10 days prior to surgery, * Cardiac surgery without cardiopulmonary bypass, * Coronary artery bypass grafting due to one or more significant coronary stenoses, * Tangential filtration blood recovery system (i-SEP SAME® type) planned for intraoperative use or absence of intraoperative blood recovery system due to investigator choice or availability issues, * Planned use of aprotinin as an antifibrinolytic agent during surgery, * Patient with contraindication to discontinuation of all antiplatelet therapy before surgery (with discontinuation at least 3 days before surgery for acetylsalicylic acid and at least 5 days before surgery for clopidogrel/ticagrelor), * Hereditary or acquired thrombophilia with or without a history of thrombosis, * History of ischemic or hemorrhagic stroke, * History of phlebitis, pulmonary embolism, or portal vein thrombosis, * History of heart at…